SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) CEO Friedhelm Blobel sold 30,000 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $10.27, for a total transaction of $308,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Friedhelm Blobel also recently made the following trade(s):

  • On Thursday, October 27th, Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total transaction of $372,000.00.
  • On Wednesday, August 17th, Friedhelm Blobel sold 501,875 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $5,018,750.00.

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) opened at 10.35 on Friday. SciClone Pharmaceuticals Inc. has a 1-year low of $7.36 and a 1-year high of $15.02. The stock has a market capitalization of $528.40 million, a PE ratio of 14.79 and a beta of 1.65. The firm has a 50-day moving average of $9.77 and a 200-day moving average of $11.36.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

A number of hedge funds and other institutional investors have recently modified their holdings of SCLN. Cornerstone Capital Management Holdings LLC. boosted its position in shares of SciClone Pharmaceuticals by 53.4% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 416,270 shares of the specialty pharmaceutical company’s stock worth $4,266,000 after buying an additional 144,900 shares during the period. Panagora Asset Management Inc. boosted its position in shares of SciClone Pharmaceuticals by 89.9% in the third quarter. Panagora Asset Management Inc. now owns 285,833 shares of the specialty pharmaceutical company’s stock worth $2,930,000 after buying an additional 135,322 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of SciClone Pharmaceuticals during the third quarter worth about $351,000. Analytic Investors LLC acquired a new position in shares of SciClone Pharmaceuticals during the third quarter worth about $803,000. Finally, Two Sigma Advisers LP boosted its position in shares of SciClone Pharmaceuticals by 19.0% in the third quarter. Two Sigma Advisers LP now owns 209,961 shares of the specialty pharmaceutical company’s stock worth $2,152,000 after buying an additional 33,500 shares during the period. 79.68% of the stock is owned by institutional investors.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

5 Day Chart for NASDAQ:SCLN

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.